NEW ZEALAND GAZETTE, No. 1

10 JANUARY 2013

Unless specific reference is made otherwise, every reference applies also to medicines that are:

(a) preparations and admixtures containing any proportion of any substance listed in the notice.

(b) salts and esters of any substance listed in the notice.

(c) preparations or extracts of biological materials listed in the notice.

(d) salts or oxides of elements listed in the notice.

Unless specific reference is made otherwise, every reference to a medicine applies:

(i) if the medicine is in an injection or eye preparation, to any concentration of that medicine; and

(ii) if the medicine is not in an injection or eye preparation, only if the concentration of the medicine is greater than 10 milligrams per litre or per kilogram.

Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol or element unless specifically stated otherwise.

Schedule 1

Prescription Medicines

5-aminolevulinic acid
Afamelanotide
Aflibercept
Amorolfine; except when specified elsewhere in this notice; except in preparations for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
Apixaban
Asenapine
Azelastine; except when specified elsewhere in this notice
Belatacept
Belimumab
Boceprevir
Cabazitaxel
Catumaxomab
Ceftaroline fosamil
Cholera vaccine; except in the form of an oral liquid containing Vibrio cholerae when sold in a pharmacy by a registered pharmacist
Cyclizine; except when specified elsewhere in this notice
Clotrimazole; except in medicines for vaginal or external use
Dapagliflozin propanediol
Degarelix
Denosumab
Diclofenac; in preparations for the treatment of solar keratosis; except when specified elsewhere in this notice; except in preparations for external use other than for the treatment of solar keratosis
Dronedarone
Econazole; except in medicines for vaginal or dermal use
Eculizumab
Eribulin mesylate
Ferric carboxymaltose
Fingolimod
Follistatin
Guaiphenesin; for oral use in medicines containing more than 2% or 200 milligrams per dose form except when specified elsewhere in this notice; except for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer’s original pack containing not more than 10 days’ supply
Icatibant
Indacaterol
Influenza vaccine; except when administered to an adult in a pharmacy by a registered pharmacist who has successfully completed the New Zealand Qualifications Authority approved vaccinator training course and who is complying with the immunisation standards of the Ministry of Health
Ingenol mebutate
Ipilimumab
Isoconazole; except in medicines for vaginal or dermal use
Linagliptin
Lixisenatide
Lovastatin; except when present as an unmodified, naturally occurring substance in a food that has not been subject to a manufacturing process other than heating, freezing, drying, preserving, bottling, canning, or packaging in retort pouches
Mercurochrome; except when specified elsewhere in this notice
Miconazole; except when specified elsewhere in this notice; except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
Nitisinone
Nomegestrol
Nystatin; except when specified elsewhere in this notice; except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
Ofatumumab
Omeprazole; except when specified elsewhere in this notice
Pantoprazole; except when specified elsewhere in this notice
Pitavastatin
Plerixafor
Prucalopride
Pseudoephedrine
Ranitidine; except when specified elsewhere in this notice; except in medicines containing 150 milligrams or less per dose unit when sold in the manufacturer’s original pack containing not more than 7 days’ supply
Remestemcel-L
Rifaximin
Rilpivirine
Rupatadine
Sapropterin
Tafluprost
Taliglucerase alfa
Telaprevir
Terbinafine; except in medicines for dermal use
Ticagrelor
Tioconazole; except in medicines for vaginal or dermal use
Tolvaptan
Trimethoprim; except in medicines for oral use containing 300 milligrams or less per dose unit when sold in a pack of 3 solid dosage units to a woman aged 16–65 years for the treatment of an uncomplicated urinary tract infection